{"entity":{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","aka":[],"tldr":"CAMBRIA-1 and CAMBRIA-2 are two adjuvant trials enrolling close to 10,000 women with early hormone-receptor-positive breast cancer to test whether the oral oestrogen-receptor degrader camizestrant should replace today's adjuvant hormone tablets, either as a switch after two to five years or from the start. Results are awaited.","summary":"CAMBRIA-1 and CAMBRIA-2, led by trial NCT05952557 and sponsored by AstraZeneca, are two adjuvant trials with a combined enrolment near 10,000 testing whether the oral SERD camizestrant should replace today's adjuvant hormone tablets in ER-positive, HER2-negative early breast cancer, either as a switch or from the start. CAMBRIA-1 switches about 4,300 patients to camizestrant after two to five years of standard endocrine therapy, and CAMBRIA-2 randomises about 5,500 patients upfront for seven years, with abemaciclib permitted in both arms, for a combined enrolment near 10,000. OnCo links them to camizestrant and to the bottleneck of dormant cells and minimal residual disease, which adjuvant endocrine therapy is meant to control. Results are awaited, and with lidERA already positive for giredestrant, whether oral SERDs become the adjuvant standard for everyone or only for those at high risk is the open question.","status":"active","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT05952557","url":"https://clinicaltrials.gov/study/NCT05952557"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["camizestrant"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05952557","phase":"3","setting":"Adjuvant ER+/HER2- early breast cancer: camizestrant vs standard endocrine therapy, either after 2-5 years of prior ET (CAMBRIA-1) or upfront (CAMBRIA-2)","sponsor":"AstraZeneca","started":"2023-10-05","startedType":"actual","enrolled":10000,"enrolledBasis":"registry","outcomes":[],"replication":"Pending."},"route":"/trials/cambria/","neighbours":{"cancer":[{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"}],"roadmap":[{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/"}]}}